Restore Medical

Company Overview

Snapshot

Founded in February 2015 by Elchanan Bruckheimer and Stephen Bellomo, Restore Medical operates with 11–50 employees. The company has raised a total of $29.43 million across 5 funding rounds and has received funding from 3 investors.

Business overview

Restore Medical is a medical device company focused on improving the treatment of congestive heart failure (CHF). The company has developed ContraBand, a transcatheter Pulmonary Artery Banding (PAB) system designed to treat HFrEF patients. This innovative and reversible therapy aims to leverage the right ventricle to support the left ventricle, improving ejection fraction and restoring optimal ventricular geometry. Restore Medical operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics categories, serving healthcare providers globally.

Strategic signal

In November 2025, Restore Medical appointed Chris Cleary, a former Medtronic executive, as Chairman of the Board. This strategic leadership addition signals a strengthening of the company's executive team and potentially indicates a focus on scaling operations and commercialization efforts for its ContraBand system, which could accelerate its market entry and adoption.

Company Intelligence Q&A

What is Restore Medical's core technology?

Restore Medical's core technology is the ContraBand system, a catheter-delivered implant designed for transcatheter Pulmonary Artery Banding (PAB) to treat Heart Failure with reduced Ejection Fraction (HFrEF) patients by leveraging the right ventricle to support the left ventricle.

When did Restore Medical receive Breakthrough Device Designation from the FDA?

In July 2024, Restore Medical received Breakthrough Device Designation from the FDA for its ContraBand system, recognizing its potential to provide a more effective treatment for HFrEF patients.

Which investor led Restore Medical's B Round funding in July 2025?

In July 2025, Pitango HealthTech led.

What was a significant leadership appointment at Restore Medical?

In November 2025, Restore Medical appointed Chris Cleary, a former Medtronic executive, as the Chairman of its Board of Directors, bringing extensive industry experience to the company.

When did Restore Medical announce successful first-in-human preliminary results for its ContraBand system?

In March 2023, Restore Medical announced successful first-in-human preliminary results for its ContraBand system in symptomatic systolic heart failure patients.